Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06058312
Other study ID # 2022/34
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 4, 2023
Est. completion date September 4, 2024

Study information

Verified date September 2023
Source Centre Antoine Lacassagne
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an exploratory study aimed at characterizing adherence to the Mediterranean diet among patients undergoing treatment for cancer, in relation to sensory alterations that occur during treatment. The primary strength of this project lies in the consideration of a large number of variables that scientific literature has shown to play a significant role in the dietary behavior of patients. The project's multidisciplinary approach, which takes into account both sensory perception and psychological dimensions, can enrich scientific knowledge on the subject, enabling a better understanding of the dietary behaviors of cancer patients undergoing treatment. One of the main strengths of the project is that taste and smell reactivity will be tested using a combined approach that includes the evaluation of responses to PROP (Propylthiouracil - a bitter compound), selected aromas and odors, responses to model foods belonging to the Mediterranean diet in which the intensities of selected sensory properties are expected to be affected by chemotherapy (e.g., sweetness and freshness). To date, no study has investigated adherence to the Mediterranean diet in such a wide range of patients. The choice of a Mediterranean diet framework is based on evidence defining this type of diet as a health promoter, improving health and preventing diseases and health complications. The Mediterranean diet includes the food variety present in the specific region chosen for the study, ensuring variety and availability of local products. The selection of the Antoine Lacassagne Center in Nice is based on the need to study the dietary preferences of a Mediterranean population familiar with Mediterranean diet products. This project could serve as the foundation for a dietary development aspect, in which foods adapted to cancer patients will be created and tested to mitigate issues of malnutrition. Expected Benefits Addressing the scientific question regarding the impact of sensory and psychological variables on adherence to the Mediterranean Diet and dietary behavior of cancer patients undergoing treatment will help identify individual variables to consider in assisting patients in adopting health-promoting behavior and reducing malnutrition. Expected Risks The research project does not involve maneuvers or the implementation of care procedures other than those to which patients would be subjected if they were not participating in the study. This research involves no specific risks, except for possible risks of allergies or food intolerances related to the sensory testing session. The dietary models used only include food ingredients normally available in markets. In order to test the taste sensitivity index, the response to propylthiouracil (PROP) will be evaluated using paper discs previously soaked in a solution composed of water and PROP according to the method of Zhao et al. (2003). This procedure has been safely used in children as well as in several studies (including patients undergoing chemotherapy) approved by ethics committees in multiple institutes from various countries. Scientific Impact The project will provide information about the variables that impact the dietary behavior of patients undergoing chemotherapy. This knowledge will be useful in developing principles that contribute to reducing malnutrition rates in oncology patients. Methodology This is an exploratory study aimed at characterizing adherence to the Mediterranean diet among patients with cancer undergoing treatment, who may experience changes in their relationship with food as well as their dietary behavior. Adherence to the Mediterranean diet will be studied in cancer patients at T0 (before the start of treatment) and at T1 (after 9 weeks of treatment). A comparison will be made between patients without sensory alterations and patients with taste and/or smell alterations at T1. The psychological and sensory variables impacting dietary behavior will also be measured and correlated with adherence to the Mediterranean diet and the presence or absence of sensory alterations.


Recruitment information / eligibility

Status Recruiting
Enrollment 442
Est. completion date September 4, 2024
Est. primary completion date September 4, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patient aged 18-70 years old, - Patient cared for at the Center Antoine Lacassagne (CAL) Day Hospital and needing to start chemotherapy or immunotherapy, - Patient to return to the Antoine Lacassagne center in their 9th week of therapy, - Patient who has not received chemotherapy or specific treatment in the 3 months prior to inclusion (wash-out period of 3 months), - Patient having read the information note and having attested to his non-objection - Patient not having objected to the use of this data in the context of medical research - Patient affiliated with a Social Security scheme. Exclusion Criteria: - Inability to eat, or patient with enteral/parenteral nutrition, - Patient who has undergone gastric surgery, - Patient undergoing radiotherapy at the level of the ENT sphere (due to the possibility of affection of the mouth due to the RTH), - Patient with cancer of the ENT sphere (upper aerodigestive tract), - Patient with an allergy or intolerance to one of the foods offered during the sensory test sessions - Vulnerable persons as defined in article L1121-5 to -8: - Pregnant women, parturients and breastfeeding mothers, - Persons deprived of their liberty by a judicial or administrative decision, persons hospitalized without consent under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8, - and persons admitted to a health or social establishment for purposes other than research, - Adults subject to a legal protection measure or unable to express their consent.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Self-questionnaire
The self-administered questionnaires to be completed at the time of inclusion will be presented to the patient on a tablet during the inclusion visit and will be completed on the same day in the Day Hospital using the Compusense software. Online self-questionnaires and sensory tests at the 9th week of treatment will also be conducted using the Compusense software in small groups at a designated location within the center.
Self-questionnaire
The MediLite questionnaire consists of nine items that assess daily consumption of fruits, vegetables, grains, meats and meat products, dairy products, alcohol, and olive oil, as well as weekly consumption of legumes and fish.
Self-questionnaire
The CITAS is a self-administered questionnaire consisting of 18 items evaluated on a five-point Likert scale and divided into three dimensions: 1) quantitative changes in taste perception (hypogeusia and ageusia), 2) qualitative changes in taste perception (heterogeusia, cacogeusia), and 3) nutrition-related problems (difficulty eating hot or fatty foods). Using a Likert scale ranging from 1 to 5 (where 1 = no difficulty or absence of disturbance and 5 = maximum difficulty or disturbance), CITAS assesses the four dimensions of taste disturbances: taste intensity, discomfort, phantogeusia, and parageusia, as well as overall taste alterations. For the original version by Kano and Kanda (2013), five items assessing changes in smell from the modified CITAS version by Drareni et al. 2021 will be added in this study.
Self-questionnaire
Food neophobia will be assessed using the Food Neophobia Scale (FNS) developed by Pliner & Hobden (1992). The FNS consists of ten statements evaluated on a 7-point agreement scale ranging from 1 = "I strongly disagree" to 7 = "I strongly agree." Individual FNS scores are calculated as the sum of the ratings given to the ten statements after reversing the neophilic items; thus, scores theoretically range from 10 to 70, with higher scores reflecting higher levels of food neophobia.
Self-questionnaire
The quality of life related to food in cancer patients is composed of 46 items with a 4-point scale (never, almost never, almost always, always). The questionnaire is divided into different subdomains: Cooking, where one eats and conviviality, Eating and drinking, After eating.
Self-questionnaire
Individual baseline disgust sensitivity is assessed using the Disgust Sensitivity-Short Form (DS-SF) questionnaire; this questionnaire is a shortened version of the disgust scale aimed at measuring disgust of animal origin, based on contamination and revulsion (Haidt, 2004; Haidt et al., 1994; Inbar, Pizarro, and Bloom, 2009; Olatunji et al., 2007). This measure consists of 8 items divided into 2 parts. In the first part, statements were rated on a scale from 1 (not at all agree-very false about me) to 5 (completely agree-very true about me); for the second part, additional statements were rated from 1 (not at all disgusting) to 5 (extremely disgusting). The total disgust sensitivity score is obtained by summing the scores after two items have been reversed and ranges from 8 to 40.
Self-questionnaire
The subscale of reward sensitivity from the short version of reward and punishment sensitivity has been selected (17 items). Each item will be assessed on a 4-point Likert scale, ranging from 1 (completely no) to 4 (completely yes).
Self-questionnaire
The EmoPrefMed questionnaire was developed to measure declared appreciation and emotional responses to selected Mediterranean diet (RM) products and changes in appreciation before and after chemotherapy. The assessment of the acceptability of a series of RM foods (listed in the questionnaire appendix) will be evaluated using a nine-point hedonic scale ranging from a minimum of 1 = "I don't like it at all" to a maximum of 9 = "I like it a lot" (Peryam & Pilgrim, 1957). Emotions will be assessed using a check-all-that-apply (CATA) list of emotions, including 4 negative and 4 positive emotions with low, moderate, and high arousal levels (It brings me joy, It intrigues me, It relaxes me, It annoys me, It leaves me indifferent, It makes me sad, It's monotonous, It disgusts me). Patients will be asked to select all the emotions they deem appropriate to describe the food product.
Self-questionnaire
Food-related attitudes will be measured using the HTAS (Health and Taste Attitude Scale) proposed by Roininen et al. (1999), consisting of six subscales focusing on perceived health and taste aspects of foods. The two scales selected in this study are general interest in health (eight items, measuring overall interest in a healthy diet) and the use of food as a reward (six items, measuring attitudes towards using food as a reward). Each subscale consists of an equal number of statements phrased positively and negatively (Roininen et al., 1999). All items were rated on a seven-point category scale, ranging from "strongly disagree" to "strongly agree." As suggested by Roininen et al. (1999), negative statements were reversed and recoded for the calculation of final scores.
Self-questionnaire
The response to PROP (6-n-propyl-2-thiouracil) is measured using 1.5 cm diameter paper disks previously soaked in a solution of deionized water with a concentration of 3.2 mM PROP, dissolving 0.5477 g/L of PROP. Each paper disk will contain approximately 0.280 mg of PROP. Participants are asked to place the paper disk on the tip of their tongue for 20 seconds, then remove it and assess the perceived bitter intensity on a Labelled Magnitude Scale (LMS). The LMS scale consists of a vertical line of 100 units with labels placed at no sensation, 0; barely detectable, 1.4; weak, 6; moderate, 17; strong, 34.7; very strong, 52.5; and the strongest imaginable sensation of any kind, 100. Numeric labels are not reported on the scale. Participants are instructed to think of the "strongest imaginable sensation" as the most intense sensation they can imagine in the realm of taste. Participants are encouraged to ask questions about the use of the scale if they need more clarification.
Self-questionnaire
The odors (Mint, Anise, Banana, Pine, Garlic, Cinnamon, Lemon) are trapped in tightly packed microcapsules (aminoplast type, diameter: 4-8 µm). Microcapsule-based ink is printed on cardboard paper (SILK-250 g; Size: 11 cm × 21 cm). Each odorant has been printed in a defined area (2 cm in diameter). The odor is released by simply rubbing the printed microcapsule reserve (scratch-and-sniff method).Patients receive a disposable single-use sample and are asked to identify the odors and evaluate on a visual analog scale the perceived intensity, perceived irritation, and appreciation of each odor.
Self-questionnaire
Two model foods were developed to investigate responses to variations in sweetness, acidity, and freshness. The first range consists of Apple-Mint Juice, composed of four samples containing different concentrations of mint syrup (0, 15, 60, 240 g/kg). The second range is a chickpea mousse made up of four samples containing different quantities of citric acid and glucose-fructose syrup (glucose-fructose syrup: 0, 50, 100, 200 g/kg; citric acid: 8, 6, 4, 4 g/kg). Participants are asked to evaluate the samples using the Labelled Affective Magnitude Scale. Regarding the LAM scale, subjects are instructed to consider the extremes of appreciation, "the best I can imagine" and "the worst I can imagine". After a break, they are asked to taste the samples again and rate the intensity of sweetness, acidity, apple flavor, mint flavor, and freshness on the Labeled Magnitude Scale: from 'not detectable' to 'the strongest imaginable'.

Locations

Country Name City State
France Centre Antoine lacassagne Nice

Sponsors (3)

Lead Sponsor Collaborator
Centre Antoine Lacassagne University of Firenze and Siena, Napoli, Italy, University of Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary role of sensory alterations The primary outcome measure of the study is the reduction in adherence score to the Mediterranean diet between T0, at inclusion, and T1, after 9 ± 2 weeks of treatment. The difference in the reduction of scores between T0 and T1 will be compared for two groups of subjects (to be formed at T1): those who report sensory alterations and those who do not. The total score of sensory alterations will be calculated based on the CiTAS questionnaire - Chemotherapy-induced Taste Alterations (Kano & Kanda, 2013). A threshold of 1.5 will be used to distinguish patients reporting taste or smell alterations (=1.5) from those not reporting them (<1.5), following Di Meglio et al. (2022).
The analysis will be conducted by comparing the MediLite score before and after 9 weeks of treatment for patients with or without sensory alterations (threshold 1.5 CITAS score).
9 weeks
Secondary Taste perception Investigate the taste perception (response to PROP, a bitter compound). The individual scores of response to PROP (propylthiouracil, a bitter compound) using the LMS (Labelled Magnitude Scale) 9 weeks
Secondary olfactory perception Investigate the olfactory perception (Sniff & scratch of 7 smells). The individual scores of response to odors using the Olfactory Test. 9 weeks
Secondary Liking for Mediterranean-type Explore the relationship between liking for Mediterranean-type products . The individual food appreciation scores (four variants of hummus and four variants of apple-mint juice) using the LAM (Labelled Affective Magnitude Scale). 9 weeks
Secondary Perceived intensity of sensations for Mediterranean-type The individual scores for the perception of the intensity of food sensations (four variants of hummus and four variants of apple-mint juice) using the LMS (Labelled Magnitude Scale). 9 weeks
Secondary Food neophobia Investigate food neophobia (FNS) with "Food Neophobia Scale (FNS) in cancer patients undergoing treatment. 9 weeks
Secondary Dietary Quality of life Investigate dietary quality of life (QVA score) in cancer patients undergoing treatment 9 weeks
Secondary relationships to health and food attitude Investigate relationships to health (general health interest-HTAS) and food (food as a reward-HTAS) 9 weeks
Secondary Sensitivity to Reward Investigate Sensitivity to Reward (SPSRQ) 9 weeks
Secondary Sensitivity to disgust Investigate Sensitivity to Disgust (DS-SF) 9 weeks
Secondary Liking and emotions mediterranean food Investigate food liking (9 hedonic point scale) and emotion (CATA emotions) using tje EmoPrefMEd questionnaire 9 weeks
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Not yet recruiting NCT02806557 - Profiling Neutrophil Counts in Patients on Chemotherapy N/A
Completed NCT02909348 - Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab